09:12 AM EDT, 08/25/2025 (MT Newswires) -- Quest Diagnostics ( DGX ) said Monday that the US Food and Drug Administration granted breakthrough device designation for its Haystack MRD test to identify MRD-positive patients with stage II colorectal cancer following treatment.

The breakthrough device designation enables sped up development, assessment, and review for premarket approval, the company said.